Filing Flows › Twist Bioscience (TWST) › Q4 FY25
Twist Bioscience (TWST) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Nov 17, 2025
Twist Bioscience (TWST) reported revenue of $99.0M for the fourth quarter fiscal 2025 (Q4 FY25), +17% from a year earlier and +3% from the quarter before. Operating margin was -30.2%, net loss $27.1M (27.4% of revenue).
Twist Bioscience, Q4 FY25: revenue $99.0M (+17% year over year), operating margin -30.2%, net loss $27.1M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $99.0M | +3% | +17% |
| Operating profit | −$29.9M | — | — |
| Net earnings | −$27.1M | -233% | — |
| Operating cash flow | −$11.8M | — | — |
What changed
Revenue was $99.0M in Q4 FY25, up 17% year over year and up 3% from the previous quarter. NGS tools was the largest line at 54% of revenue.
Operating costs exceeded revenue by $29.9M, an operating margin of -30.2%. Total costs grew 7% against revenue growth of 17%. The fastest-growing cost line was SG&A (+20%). The quarter ended with a net loss of $27.1M, after a profit of $20.4M the previous quarter.
Operating cash flow was −$11.8M. Non-cash charges added back $6.0M of depreciation and amortization and $16.1M of share-based compensation. Working capital and other items used $6.8M. Capital expenditures of $12.4M exceeded it, leaving free cash flow of −$24.2M.
Questions
What was Twist Bioscience's revenue in the fourth quarter fiscal 2025?
Twist Bioscience (TWST) reported revenue of $99.0M for the fourth quarter fiscal 2025 (Q4 FY25), +17% from a year earlier and +3% from the quarter before.
Was Twist Bioscience profitable in the fourth quarter fiscal 2025?
Operating loss was $29.9M (-30.2% of revenue) and net loss $27.1M.
Source: Twist Bioscience 10-K on SEC EDGAR.